All In Biotech

Drug Trial Radar · NCT05527184

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers

Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

256

Actual

Start

Jan 11, 2023

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.

Conditions

  • Endometrial Cancer
  • High Grade Serous Adenocarcinoma of Ovary
  • Primary Peritoneal Carcinoma
  • Fallopian Tube Cancer
  • Cervical Cancer

Interventions

  • IMGN151Drug

    IMGN151 is an antibody-drug conjugate (ADC).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to approximately 3 years
  2. Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Day 21 of Cycle 1 (Cycle length = 3 weeks)
  3. Recommended Dose of IMGN151 MonotherapyTime frame: Up to approximately 2 years

Locations

58 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham /ID# 269045

    Birmingham, Alabama

  • City of Hope National Medical Center /ID# 269036

    Duarte, California

  • Moores Cancer Center /ID# 269040

    La Jolla, California

  • University of California Los Angeles Medical Center /ID# 269037

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian /ID# 269047

    Newport Beach, California

  • UCHSC Anschultz Cancer Pavilion /ID# 269056

    Aurora, Colorado

  • AdventHealth Celebration /ID# 269030

    Kissimmee, Florida

  • Mount Sinai Medical Center /ID# 269050

    Miami, Florida

  • Miami Cancer Institute at Baptist Health /ID# 269041

    Miami, Florida

  • Florida Cancer Specialists- Sarasota Cattlemen /ID# 269055

    Sarasota, Florida

  • University of Chicago Medical Center /ID# 269028

    Chicago, Illinois

  • Massachusetts General Hospital /ID# 278119

    Boston, Massachusetts

  • Dana-Farber Cancer Institute /ID# 269039

    Boston, Massachusetts

  • Karmanos Cancer Institute - Detroit /ID# 269052

    Detroit, Michigan

  • University of Mississippi Medical Cancer Center /ID# 269046

    Jackson, Mississippi

  • Washington University School of Medicine - St. Louis /ID# 269048

    St Louis, Missouri

  • Holy Name Medical Center /ID# 269051

    Teaneck, New Jersey

  • Roswell Park Cancer Institute /ID# 269043

    Buffalo, New York

  • Long Island Jewish Medical Center /ID# 269035

    New Hyde Park, New York

  • Columbia University Irving Medical Center /ID# 269033

    New York, New York

  • University of Rochester Medical Center /ID# 269044

    Rochester, New York

  • University of North Carolina Medical Center /ID# 269027

    Chapel Hill, North Carolina

  • Atrium Health Levine Cancer Institute /ID# 269049

    Charlotte, North Carolina

  • The Ohio State University Comprehensive Cancer Center /ID# 269026

    Columbus, Ohio

  • OU Health - Stephenson Cancer Center /ID# 269025

    Oklahoma City, Oklahoma

  • University of Pennsylvania /ID# 269042

    Philadelphia, Pennsylvania

  • West Penn Hospital /ID# 269054

    Pittsburgh, Pennsylvania

  • Women & Infants Hospital /ID# 269032

    Providence, Rhode Island

  • Sanford Cancer Center /ID# 269038

    Sioux Falls, South Dakota

  • Tennessee Oncology Nashville /ID# 269029

    Nashville, Tennessee

  • MD Anderson Houston /ID# 269057

    Houston, Texas

  • University of Virginia /ID# 269053

    Charlottesville, Virginia

  • Monash Health - Monash Medical Centre /ID# 268971

    Perth, Western Australia, Australia

  • Hôpital Vivalia De Libramont /ID# 268979

    Libramont-Chevigny, Luxembourg, Belgium

  • Universitair Ziekenhuis Leuven /ID# 268977

    Leuven, Vlaams-Brabant, Belgium

  • Cross Cancer Institute /ID# 268984

    Edmonton, Alberta, Canada

  • BC Cancer - Kelowna /ID# 268983

    Kelowna, British Columbia, Canada

  • Centre Hospitalier De L'Universite De Montreal - Hopital Saint-Luc /ID# 268982

    Montreal, Quebec, Canada

  • Centre Hospitalier Universite De Sherbrooke - Hôtel-Dieu Hospital /ID# 268981

    Sherbrooke, Quebec, Canada

  • Institut Gustave Roussy /ID# 268994

    Villejuif, Île-de-France Region, France

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.